BusinessTESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDABy Nasdaq OMXMay 1, 2017, 12:32 PM UTC
BusinessTeneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine ReleaseBy Nasdaq OMXMay 1, 2017, 12:01 PM UTC
BusinessMerus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate DevelopmentsBy Nasdaq OMXApr 28, 2017, 8:47 PM UTC
BusinessTESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042By Nasdaq OMXApr 27, 2017, 12:15 PM UTC
BusinessOncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017By Nasdaq OMXApr 5, 2017, 12:01 PM UTC
BusinessOncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017By Nasdaq OMXApr 5, 2017, 12:01 PM UTC
BusinessOncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017By Nasdaq OMXApr 3, 2017, 5:00 PM UTC
BusinessPeregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target ToxicitiesBy Nasdaq OMXApr 3, 2017, 12:05 PM UTC
